Why Medpace (MEDP) Outpaced the Stock Market Today

Medpace (MEDP) closed the most recent trading day at $466.80, moving +1.32% from the previous trading session. The stock’s change was more than the S&P 500’s daily gain of 0.54%. Elsewhere, the Dow gained 0.66%, while the tech-heavy Nasdaq added 0.77%.

Coming into today, shares of the provider of outsourced clinical development services had gained 4.19% in the past month. In that same time, the Medical sector lost 8.43%, while the S&P 500 lost 4.71%.

The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on April 22, 2026. It is anticipated that the company will report an EPS of $3.74, marking a 1.91% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $694.24 million, up 24.29% from the year-ago period.

MEDP’s full-year Zacks Consensus Estimates are calling for earnings of $17.04 per share and revenue of $2.81 billion. These results would represent year-over-year changes of +11.52% and +11.17%, respectively.

Investors might also notice recent changes to analyst estimates for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts’ favorable outlook on the business health and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).

Investors should also note Medpace’s current valuation metrics, including its Forward P/E ratio of 27.04. This signifies a premium in comparison to the average Forward P/E of 15.02 for its industry.

Meanwhile, MEDP’s PEG ratio is currently 2.21. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.38.